Skip to main content
. 2020 Oct 10;6:100. doi: 10.1038/s41420-020-00337-4

Fig. 1. A scheme that illustrates major mechanisms of action by Her2-targeting agents.

Fig. 1

Antibody-based therapeutics pertuzamab and trastuzamab interact with the extracellular domain of Her2. Tyrosin kinasse inhibitors (lapatinib, neratinib, and pyrotinib) interact with the intracellular domain of Her2.